SCHEMBL3586266

SCHEMBL3586266

CS(=O)(=O)N(c1ccc(Nc2ncc3cnn(-c4ccc(OCc5ccccc5)c5c4CCCC5)c3n2)cc1)S(C)(=O)=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AURKA O14965 14/20 0.42
CDK1 P06493 14/20 0.42
CCNB1 P14635 14/20 0.42
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CCND2 P30279 1/20 0.35
CCND3 P30281 1/20 0.35
FGFR4 P22455 1/20 0.35
AXL P30530 1/20 0.34
FLT3 P36888 1/20 0.34
MERTK Q12866 1/20 0.34
GLO1 Q04760 1/20 0.34
CDK2 P24941 1/20 0.34
CDK9 P50750 1/20 0.34
FGFR1 P11362 1/20 0.34
SRC P12931 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3575913 0.90 NPC1 (0.41) AURKACDK1CCNB1CDK4CCND1
SCHEMBL3587627 0.85 CDK4 (0.35) AURKACDK1CYP3A4CYP2C9CDK4
SCHEMBL3587869 0.83 CDK1 (0.47) AURKACDK1CCNB1CYP3A4CYP2C9
SCHEMBL3580939 0.82 CDK4 (0.53) AURKACDK1CCNB1CDK4CCND1
SCHEMBL3589708 0.81 STAT6 (0.52) AURKACDK1CCNB1CDK4CCND1
SCHEMBL1355558 0.77 CDK1 (0.48) AURKACDK1CCNB1CYP3A4CYP2C9
SCHEMBL3580945 0.76 AURKA (0.46) AURKACDK1CCNB1FLT3CDK2
SCHEMBL3573049 0.75 CDK1 (0.46) AURKACDK1CCNB1CYP3A4CYP2C9
SCHEMBL3588130 0.75 AURKA (0.39) AURKACDK1CCNB1CYP3A4CYP2C9
SCHEMBL1356000 0.74 AURKA (0.44) AURKACDK1CCNB1CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190787-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC 2010-07-29 US claimed
EP-2108019-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP claimed
WO-2008094575-A2 1-H-PYRAZOLO(3,4B)PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO claimed
US-20100190787-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC 2010-07-29 US disclosed
EP-2108019-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP disclosed
WO-2008094575-A2 1-H-PYRAZOLO(3,4B)PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190787-A1 Modulators of Mitotic Kinases CDK1, BUB1, BUB1B AURKA 10/4885CDK1 1/4885CCNB1 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.